非酒精性脂肪性肝病：一种多系统疾病*

doi:10.3969/j.issn.1672-5069.2017.03.001

Abstract

Jin Peihua, Shi Junping. Nonalcoholic fatty liver disease: A multisystem disease[J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2017, 20(3): 257-259.

[1] Armstrong MJ,Adams LA,Canbay A,et al.Extrahepatic complications of nonalcoholic fatty liver disease. Hepatology,2014,59:1174-1197.
[2] Fan JG,Li F,Cai XB,et al.Effects of nonalcoholic fatty liver disease on the development of metabolic disorders.J Gastroenterol Hepatol,2007,22:1086-1091.
[3] Vernon G,Baranova A,Younossi ZM.Systematic review:the epidemiolory and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults. Aliment Pharmacol Ther,2011,34:274-285.
[4] Sung KC,Jeong WS,Wild SH,et al.Combined influence of insulin resistance,overweight/obesity,and fatty liver as risk factors for type 2 diabetes. Diabetes Care,2012,35:717-722.
[5] Masuoka HC,Chalasani N.Nonalcoholic fatty liver disease:an emerging threat to obese and diabetic individuals. Ann N Y Acad Sci,2013,1281:106-122.
[6] Balkau B,Lange C,Vol S,et al.Nine-year incident diabetes is predicted by fatty liver indices:the French D.E.S.I.R. study. BMC Gastroenterol,2010,10:56.
[7] Shibata M,Kihara Y,Taguchi M,et al.Nonalcoholic fatty liver disease is a risk factor for type 2 diabetes in middle-aged Japanese men. Diabetes Care,2007,30:2940-2944.
[8] Zoppini G,Fedeli U,Gennaro N,et al.Mortality from chronic liver diseases in diabetes. Am J Gastroenterol,2014,109:1020-1025.
[9] Anstee QM,Targher G,Day CP.Progression of NAFLD to diabetes mellitus,cardiovascular disease or cirrhosis. Nat Rev Gastroenterol Hepatol,2013,10:330-344.
[10] Sinn DH,Kang D,Chang Y,et al.Non-alcoholic fatty liver disease and progression of coronary artery calcium score:a retrospective cohort study. Gut,2016,66(2):311854.
[11] Wong VW,Wong GL,Yip GW,et al.Coronary artery disease and cardiovascular outcomes in patients with non-alcoholic fatty liver disease. Gut,2011,60:1721-1727.
[12] Targher G,Day CP,Bonora E.Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease. N Engl J Med,2010,363:1341-1350.
[13] Lu H,Liu H,Hu F,et al.Independent Association between Nonalcoholic Fatty Liver Disease and Cardiovascular Disease:A systematic review and Meta-analysis. Int J Endocrinol,2013,2013(2013):124958.
[14] Targher G,Chonchol MB,Byrne CD.CKD and nonalcoholic fatty liver disease. Am J Kidney Dis,2014,64:638-652.
[15] Musso G,Gambino R,Cassader M,et al.Meta-analysis:natural history of non-alcoholic fatty liver disease(NAFLD) and diagnostic accuracy of non-invasive tests for liver disease severity. Ann Med,2011,43(8):617-649.
[16] Arase Y,Suzuki F,Kobayashi M,et al.The development of chronic kidney disease in Japanese patients with nonalcoholic fatty liver disease. Intern Med,2011,50:1081-1087.
[17] Yasui K,Sumida Y,Mori Y,et al.Nonalcoholic steatohepatitis and increased risk of chronic kidney disease. Metabolism,2011,60:735-739.
[18] Xu C,Wan X,Xu L,et al.Xanthine oxidase in non-alcoholic fatty liver disease and hyperuricemia:One stone hits two birds. J Hepatol,2015,62(6):1412-1419.
[19] Li Y,Xu C,Yu C,et al.Association of serum uric acid level with non-alcoholic fatty liver disease:a cross-sectional study. J Hepatol,2009,50(5):1029-1034.
[20] Bonora E,Targher G.Increased risk of cardiovascular disease and chronic kidney disease in NAFLD. Nat Rev Gastroenterol Hepatol,2012,9:372-381.
[21] Targher G,Chonchol M,Zoppini G,et al.Risk of chronic kidney disease in patients with non-alcoholic fatty liver disease: is there a link [J] Hepatol,2011,54:1020-1029.
[22] Hamaguchi M,Kojima T,Takeda N,et al.Nonalcoholic fatty liver disease is a novel predictor of cardiovascular disease. World J Gastroenterol,2007,13:1579-1584.

Nonalcoholic fatty liver disease: A multisystem disease

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	Ren Yufei, Chen Xiaoqing, Kong Weizong, et al.. Effect of salvianolic acid B on autophagy in nonalcoholic fatty liver disease cell model in vitro [J]. Journal of Practical Hepatology, 2019, 22(6): 804-807.
[2]	Li Yingyi, Guo Cuifen, Zhang Ruinan, et al.. Correlation of polymorphism of ALDH2 rs671 to morbidity in individuals prone to nonalcoholic fatty liver disease [J]. Journal of Practical Hepatology, 2019, 22(6): 848-851.
[3]	Zhang Mei, Shi Xiuying, Li Linjuan, et al. Hepatic expression of interferon inducible protein -10 in patients with hepatitis B liver cirrhosis and hepatogenic diabetes mellitus [J]. Journal of Practical Hepatology, 2019, 22(5): 688-691.
[4]	Zhang Lanhua, Shao Qin, Xia Zhenjuan. Changes of serum 25-(OH) D3 and IL-17 levels are associated with progress of nonalcoholic fatty liver disease in obese children [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(4): 522-525.
[5]	Zhang Tingting, Wang Xuan. Clinical implications of oral glucose tolerance test in cirrhotic patients with hepatogenous diabetes [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(3): 449-452.
[6]	Huo Huiqin, Gong Xiaohong, Li Zhenghong. Assessment of right atrial and ventricular functions in patients with nonalcoholic fatty liver disease-induced liver cirrhosis by real-time three-dimensional echocardiography and speckle tracking imaging [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(2): 244-247.
[7]	Xie Xiao, Lu Lungen. Noninvasive diagnosis and assessment of patients with nonalcoholic steatohepatitis [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(2): 301-306.
[8]	Song Na, Liu Xiaoyan, Liu Chang, et al.. Changes of plasma thyrotropin levels in patients with nonalcoholic fatty liver disease and type 2 diabetes [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(1): 65-68.
[9]	Zhong Yan, Su Shuting, Mi Yuqiang.. Treatment of patients with nonalcoholic fatty liver disease [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(1): 145-148.
[10]	Huang Jiaofeng, Lin Su, Wang Mingfang, et al.. Impact of entecavir therapy on hepatic steatosis in patients with chronic hepatitis B and nonalcoholic fatty liver disease [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2018, 21(6): 863-867.
[11]	Huang Faguang, Li Xiaocheng, Gong Jianping, et al.. Research on insulin resistance related protein molecules in human liver tissues by comprehensive gene expression profiling analysis [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2018, 21(6): 872-876.
[12]	Pu Yonglan, Chen Yuanwen, Fan Jiangao.. Gluten intestinal disease and nonalcoholic fatty liver: One case report [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2018, 21(6): 981-982.
[13]	Ge Jianxiang, Sun Yezi, Zhao Yun.. Application of entecavir in the treatment of patients with HBV-related cirrhosis complicated by hepatogenous diabetes and its influence on indexes of glucose metabolism [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2018, 21(5): 677-680.
[14]	Yan Chenli, Wang Jingjing, Wang Jun.. Severity of coronary artery lesions and risk factors in patients with nonalcoholic fatty liver disease complicated by coronary heart disease [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2018, 21(5): 737-740.
[15]	Bing Hao, Li Yiling.. Correlation between non-alcoholic fatty liver disease and hepatocellular carcinoma:Fact or fiction [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2018, 21(5): 821-824.